A phase II trial of oral temozolomide in patients with metastatic renal cell cancer

D. Park; C. Ryan; M. Dolan; N. Vogelzang; W. Stadler

doi:10.1007/s00280-002-0473-z

A phase II trial of oral temozolomide in patients with metastatic renal cell cancer

D. Park, C. Ryan, M. Dolan, N. Vogelzang, W. Stadler

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Purpose: To determine the activity of temozolomide, an oral imidazotetrazine alkylating agent that has exhibited broad antitumor activity in preclinical studies, in renal cell cancer (RCC) patients. Methods: Metastatic RCC patients were treated with temozolomide, 200 mg/m² per day orally, and traditional radiologic response endpoints were assessed. O⁶-Alkylguanine-DNA alkyltransferase (AGT) activity was measured in four pretreatment biopsies. Results: Among 12 patients, there were no responses. High AGT activity was observed in all four biopsies analyzed. Conclusions: Temozolomide is not active against RCC and this clinical observation may be due to high levels of AGT in this tumor.

Original language	English (US)
Pages (from-to)	160-162
Number of pages	3
Journal	Cancer Chemotherapy and Pharmacology
Volume	50
Issue number	2
DOIs	https://doi.org/10.1007/s00280-002-0473-z
State	Published - 2002
Externally published	Yes

Keywords

DNA repair
O-Alkylguanine-DNA alkyltransferase
Phase II trial
Renal cell cancer

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

Access to Document

10.1007/s00280-002-0473-z

Cite this

@article{68691bab192944fcab846f4ad2773d16,

title = "A phase II trial of oral temozolomide in patients with metastatic renal cell cancer",

abstract = "Purpose: To determine the activity of temozolomide, an oral imidazotetrazine alkylating agent that has exhibited broad antitumor activity in preclinical studies, in renal cell cancer (RCC) patients. Methods: Metastatic RCC patients were treated with temozolomide, 200 mg/m2 per day orally, and traditional radiologic response endpoints were assessed. O6-Alkylguanine-DNA alkyltransferase (AGT) activity was measured in four pretreatment biopsies. Results: Among 12 patients, there were no responses. High AGT activity was observed in all four biopsies analyzed. Conclusions: Temozolomide is not active against RCC and this clinical observation may be due to high levels of AGT in this tumor.",

keywords = "DNA repair, O-Alkylguanine-DNA alkyltransferase, Phase II trial, Renal cell cancer",

author = "D. Park and C. Ryan and M. Dolan and N. Vogelzang and W. Stadler",

note = "Funding Information: This work was s upported in part by Schering-Plough, Inc., and the University of Chicago Cancer Research Center, N01CM07003.",

year = "2002",

doi = "10.1007/s00280-002-0473-z",

language = "English (US)",

volume = "50",

pages = "160--162",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - A phase II trial of oral temozolomide in patients with metastatic renal cell cancer

AU - Park, D.

AU - Ryan, C.

AU - Dolan, M.

AU - Vogelzang, N.

AU - Stadler, W.

N1 - Funding Information: This work was s upported in part by Schering-Plough, Inc., and the University of Chicago Cancer Research Center, N01CM07003.

PY - 2002

Y1 - 2002

N2 - Purpose: To determine the activity of temozolomide, an oral imidazotetrazine alkylating agent that has exhibited broad antitumor activity in preclinical studies, in renal cell cancer (RCC) patients. Methods: Metastatic RCC patients were treated with temozolomide, 200 mg/m2 per day orally, and traditional radiologic response endpoints were assessed. O6-Alkylguanine-DNA alkyltransferase (AGT) activity was measured in four pretreatment biopsies. Results: Among 12 patients, there were no responses. High AGT activity was observed in all four biopsies analyzed. Conclusions: Temozolomide is not active against RCC and this clinical observation may be due to high levels of AGT in this tumor.

AB - Purpose: To determine the activity of temozolomide, an oral imidazotetrazine alkylating agent that has exhibited broad antitumor activity in preclinical studies, in renal cell cancer (RCC) patients. Methods: Metastatic RCC patients were treated with temozolomide, 200 mg/m2 per day orally, and traditional radiologic response endpoints were assessed. O6-Alkylguanine-DNA alkyltransferase (AGT) activity was measured in four pretreatment biopsies. Results: Among 12 patients, there were no responses. High AGT activity was observed in all four biopsies analyzed. Conclusions: Temozolomide is not active against RCC and this clinical observation may be due to high levels of AGT in this tumor.

KW - DNA repair

KW - O-Alkylguanine-DNA alkyltransferase

KW - Phase II trial

KW - Renal cell cancer

UR - http://www.scopus.com/inward/record.url?scp=0036351280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036351280&partnerID=8YFLogxK

U2 - 10.1007/s00280-002-0473-z

DO - 10.1007/s00280-002-0473-z

M3 - Article

C2 - 12172983

AN - SCOPUS:0036351280

SN - 0344-5704

VL - 50

SP - 160

EP - 162

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 2

ER -

A phase II trial of oral temozolomide in patients with metastatic renal cell cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this